Rozrolimupab is a recombinant antibody mixture specifically containing 25 Rhesus D or RhD human antibodies and is currently under development by Symphogen for the treatment of immune thrombocytopenic purpura (ITP) and for the prevention of hemolytic disease of the newborn (HDN).
ATC prefix
none
CAS number
909402-77-3
IUPAC name
1. Anti-RhD recombinant human polyclonal antibody composed of 25 unique IgG1 antibodies, 2. Recombinant human antigen-specific polyclonal antibody (pAb) against RhD antigen expressed in Chinese hamster ovary cells
This page contains content from the copyrighted Wikipedia article "Rozrolimupab"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.